{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-007598","form_type":"8-K","ticker":"TLSI","cik":"0001826667","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2026-02-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.388133+00:00","generated_at":"2026-05-16T01:31:34.346006+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"TriSalus prices $40M public offering of 9.76M shares at $4.10/share","bullets":["Gross proceeds ~$40.0M from 9,756,100 shares at $4.10/share; net proceeds ~$37.0M (before over-allotment).","Underwriters granted 30-day option to purchase up to 1,463,415 additional shares (15% of offering).","Offering expected to close February 23, 2026; Lake Street Capital Markets sole book-runner.","Net proceeds estimated at ~$42.64M if over-allotment fully exercised.","Proceeds for general corporate purposes including working capital and G&A."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-007598","json":"https://secwatch.observer/filing/0001493152-26-007598.json","markdown":"https://secwatch.observer/filing/0001493152-26-007598.md","text":"https://secwatch.observer/filing/0001493152-26-007598.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826667/000149315226007598/0001493152-26-007598-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826667/000149315226007598/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:31:34.346006+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8d3bb718842ea8132b8c24e6786efe87f03ad44b","claim":"TriSalus Life Sciences, Inc. entered into Underwriting Agreement with Lake Street Capital Markets, LLC (effective 2026-02-19).","evidence_excerpt":"On February 19, 2026, TriSalus Life Sciences, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Lake Street Capital Markets, LLC (“LSCM”), as representative of the underwriters named therein (the “Underwriters”), relating to the public offering (the “Offering”) of 9,756,100 shares (the “Shares”) of common stock of the Company, par value $0.0001 per share (the “Common Stock”), at a price to the public of $4.10 per Share (the “Offering Price”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000149315226007598/0001493152-26-007598-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Lake Street Capital Markets, LLC"},{"label":"Effective","value":"2026-02-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}